Abbott Laboratories (NYSE:ABT) Holdings Decreased by Barry Investment Advisors LLC

Barry Investment Advisors LLC cut its position in shares of Abbott Laboratories (NYSE:ABT) by 8.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,314 shares of the healthcare product maker’s stock after selling 201 shares during the quarter. Barry Investment Advisors LLC’s holdings in Abbott Laboratories were worth $255,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Perigon Wealth Management LLC raised its stake in Abbott Laboratories by 5.2% during the fourth quarter. Perigon Wealth Management LLC now owns 47,080 shares of the healthcare product maker’s stock worth $5,182,000 after acquiring an additional 2,317 shares during the period. Boston Partners lifted its holdings in shares of Abbott Laboratories by 634.6% in the 3rd quarter. Boston Partners now owns 29,758 shares of the healthcare product maker’s stock worth $2,882,000 after purchasing an additional 25,707 shares during the last quarter. VisionPoint Advisory Group LLC boosted its position in Abbott Laboratories by 7.4% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 3,106 shares of the healthcare product maker’s stock valued at $301,000 after purchasing an additional 215 shares during the period. Gradient Investments LLC grew its stake in Abbott Laboratories by 4.7% during the 4th quarter. Gradient Investments LLC now owns 257,508 shares of the healthcare product maker’s stock worth $28,344,000 after buying an additional 11,508 shares during the last quarter. Finally, BKM Wealth Management LLC bought a new stake in Abbott Laboratories in the fourth quarter valued at $2,111,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

ABT stock traded up $1.88 during trading hours on Wednesday, hitting $104.84. 4,106,536 shares of the stock traded hands, compared to its average volume of 5,628,488. The company has a current ratio of 1.60, a quick ratio of 1.11 and a debt-to-equity ratio of 0.32. The stock has a 50-day simple moving average of $108.89 and a 200 day simple moving average of $109.54. Abbott Laboratories has a one year low of $89.67 and a one year high of $121.64. The company has a market cap of $182.38 billion, a P/E ratio of 32.64, a P/E/G ratio of 2.48 and a beta of 0.76.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.02. The company had revenue of $9.96 billion for the quarter, compared to analysts’ expectations of $9.88 billion. Abbott Laboratories had a net margin of 13.96% and a return on equity of 20.18%. The business’s revenue was up 2.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.03 EPS. Equities analysts forecast that Abbott Laboratories will post 4.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ABT shares. Barclays dropped their price objective on shares of Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a report on Monday, April 22nd. Raymond James reaffirmed a “buy” rating and set a $124.00 price target on shares of Abbott Laboratories in a report on Wednesday, April 24th. Citigroup decreased their price objective on Abbott Laboratories from $128.00 to $119.00 and set a “buy” rating for the company in a report on Wednesday. Royal Bank of Canada cut their target price on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research note on Thursday, April 18th. Finally, Evercore ISI raised their price target on Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $120.60.

Insider Activity

In related news, VP John A. Jr. Mccoy sold 472 shares of Abbott Laboratories stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the transaction, the vice president now owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $118.50, for a total transaction of $55,932.00. Following the sale, the vice president now directly owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Jr. Robert E. Funck sold 10,097 shares of the firm’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $104.57, for a total value of $1,055,843.29. Following the completion of the sale, the executive vice president now directly owns 211,341 shares of the company’s stock, valued at approximately $22,099,928.37. The disclosure for this sale can be found here. In the last 90 days, insiders sold 46,884 shares of company stock worth $5,153,916. Insiders own 0.47% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.